A case-control study on direct oral anticoagulants versus warfarin for acute pulmonary embolism in obese patients
C. Samaranayake (London, United Kingdom), C. Mccabe (London, United Kingdom), S. Slader (Brisbane, Australia), T. Tseng (Brisbane, Australia), K. Tran (Brisbane, Australia), J. Anderson (Brisbane, Australia), L. Price (London, United Kingdom), S. Wort (London, United Kingdom), A. Mccann (Brisbane, Australia), G. Keir (Brisbane, Australia), J. Upham (Brisbane, Australia)
Source: Virtual Congress 2021 – Insights into pulmonary embolism
Session: Insights into pulmonary embolism
Session type: Oral Presentation
Number: 2589
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Samaranayake (London, United Kingdom), C. Mccabe (London, United Kingdom), S. Slader (Brisbane, Australia), T. Tseng (Brisbane, Australia), K. Tran (Brisbane, Australia), J. Anderson (Brisbane, Australia), L. Price (London, United Kingdom), S. Wort (London, United Kingdom), A. Mccann (Brisbane, Australia), G. Keir (Brisbane, Australia), J. Upham (Brisbane, Australia). A case-control study on direct oral anticoagulants versus warfarin for acute pulmonary embolism in obese patients. 2589
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Use of direct oral anticoagulants for acute pulmonary embolisms in obesity: a propensity-matched, multicentre case–control study Source: ERJ Open Res, 7 (3) 00379-2021; 10.1183/23120541.00379-2021 Year: 2021
Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials Source: Eur Respir J, 50 (3) 1701097; 10.1183/13993003.01097-2017 Year: 2017
Comparison of two regimens of oral anticoagulation in pulmonary embolism Source: Eur Respir J 2006; 28: Suppl. 50, 632s Year: 2006
Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019
Direct oral anticoagulant use and thrombus detection in patients with chronic thromboembolic pulmonary hypertension referred for pulmonary thromboendarterectomy Source: International Congress 2019 – Chronic thromboembolic pulmonary hypertension Year: 2019
Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli Source: ERJ Open Res, 7 (1) 00554-2020; 10.1183/23120541.00554-2020 Year: 2021
Have we found how to identify candidates for thrombolysis among normotensive patients with acute pulmonary embolism? Source: Eur Respir J 2016; 47: 1054-1056 Year: 2016
Systemic corticosteroids and the risk of venous thromboembolism in COPD patients: A nationwide study of 30.473 outpatients with severe-very severe COPD Source: Virtual Congress 2021 – Insights into pulmonary embolism Year: 2021
Impact of patients’ setting on the prevalence of pulmonary embolism in acute exacerbation of COPD : a meta-analysis of observational studies. Source: International Congress 2017 – Pulmonary embolism Year: 2017
Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor? Source: Eur Respir J, 55 (1) 1902323; 10.1183/13993003.02323-2019 Year: 2020
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor? Source: Eur Respir J, 55 (1) 1902028; 10.1183/13993003.02028-2019 Year: 2020
The outcome of anticoagulation alone therapy for patients with submassive pulmonary embolism Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019
Hokusai post-PE study: a follow-up study on long-term outcomes of pulmonary embolism in patients treated with edoxaban vs warfarin Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism Year: 2020
Supervised exercise training in patients with chronic thromboembolic pulmonary hypertension (CTEPH) as early follow-up treatment after pulmonary endarterectomy (PEA) – a prospective cohort study Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020
Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020
Effect of statin therapy in patients with lung cancer on mortality, incidence of infections and pulmonary embolism Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012
Coronary artery disease risk score calculation and evaluation of statin and antithrombotic drug use among patients admitted with an acute exacarbation of COPD Source: Annual Congress 2008 - Issues in the management of COPD in the community Year: 2008
Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019
Should thrombolysis and sildenafil be given in the acute management of patients with large pulmonary embolism? An assessment of the short and long-term outcomes. Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019